Advanced Oncotherapy (AVO) – Conversion of loan notes
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share […]
Advanced Oncotherapy (AVO) – Conversion of Convertible Loan Notes
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of […]
Advanced Oncotherapy (AVO) – Non-exec Professor Steve Myers buys 400,000 shares at 26p.
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers, Non-Executive Director of the Company, has purchased today a total of 400,000 ordinary shares of 25 pence in the Company at a price of 26 pence per Ordinary Share. Following this transaction, Professor Myers holds 450,569 Ordinary […]
Directors Talk – Q&A with Michel Baelen, Head of Regulatory Affairs at Advanced Oncotherapy Plc
Article published by Directors Talk Q&A: Advanced Oncotherapy Plc Michel Baelen, Head of Regulatory Affairs Posted by: giles.arbor 10th May 2017 Michel Baelen, head of Regulatory Affairs at Advanced Oncotherapy plc (LON:AVO), talks to DirectorsTalk about the attraction of joining AVO, his past roles and how this experience benefits the company, work done to date […]
Advanced Oncotherapy (AVO) – Non-Exec Professor Chris Nutting buys 202,500 shares at 24.67p
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company at an average price of 24.67 pence per Ordinary Share. […]
Advanced Oncotherapy (AVO) – Non-Exec Dr Nick Plowman invests GBP250,000 at 30p per share
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Nick Plowman, Non-Executive Director, will invest £250,000 in the Company. The investment will be satisfied through the issue of 833,333 new ordinary shares of 25 pence nominal value in the capital of the Company at a price of […]
North America Radiotherapy Market by Equipment Type (Linear Accelerators, Radiation Therapy Simulators and Treatment Planning Systems)
The North America Radiotherapy Market was worth $1,798 million in 2016 and estimated to be growing at a CAGR of 5.54%, to reach $2,355 million by 2021. By Abishek. (EMAILWIRE.COM, May 02, 2017 ) According to the report North America Radiotherapy Market by Type, by Application, by Equipment Type and by Region – Industry […]
Advanced Oncotherapy (AVO) – Holdings in company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]
Advanced Oncotherapy (AVO) – Holdings in company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights √ An acquisition or disposal of qualifying financial […]
Advanced Oncotherapy (AVO) – Update on Bracknor financing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the notification on 22 February 2017, the Company has drawn down the second tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche). Proceeds will continue to […]